Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.43 · Revenue $0.00 · 1 analysts
Est. EPS $0.37 · Revenue $0.00 · 1 analysts
Est. EPS $4.47 · Revenue $1.25M · 1 analysts
Est. EPS $-0.82 · Revenue $778593.00 · 1 analysts
$0.00 per share
$0.00 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $2.0M | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $64.0M | +436.0% | +104.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +0.7% | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -754.4% | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +3202.5% | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-11.1M | -31.4% | +93.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -553.9% | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.4% | +62.4% | -27.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.98x | -72.3% | -22.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $230.9M | +48.7% | +37.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 1.50 vs -0.34 | +541.2% | 1.84 vs 2.76 | -33.3% |
| Revenue Surprise | $2.0M vs $2.0M | 0.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Hexter Joshua | officer: COO & CBO | Common Stock | A | 50,000 | $3.69 |
| Jul 2, 2026 | Hexter Joshua | officer: COO & CBO | Stock option (right to buy) | D | 50,000 | $3.69 |
| Jul 1, 2026 | Hexter Joshua | officer: COO & CBO | Common Stock | D | 137,000 | $4.46 |
| Jul 1, 2026 | Gabay Avraham | officer: Chief Financial Officer | Common Stock | D | 73,360 | $4.51 |
| Mar 30, 2026 | KIDRON NADAV | director, officer: President and CEO | Common Stock | D | 44,818 | $3.31 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Nadav Kidron | President, Chief Executive Officer & Executive Chairman | USD 1,065,391 | Male | 1974 | Active |
Miriam Kidron | Chief Scientific Officer & Director | USD 760,351 | — | 1940 | Active |
Joshua Hexter | Chief Operating & Business Officer | USD 583,333 | Male | 1970 | Active |
Avraham Gabay | Chief Financial Officer, Treasurer & Secretary | USD 303,065 | Male | 1986 | Active |
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026) Oramed to Join the Russell 2000 and Russell 3000 Indexes this week NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026.
Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD Technology to Lifeward, securing a 49.9% stake and potential revenue streams for ReWalk. Strategic investments in biotech and real estate diversify risk, but cash burn and limited liquidity raise near-term funding concerns.
